Loading...
Projects / Programmes source: ARIS

Peptidic inhibitors of lipopolysaccharide

Research activity

Code Science Field Subfield
1.09.00  Natural sciences and mathematics  Pharmacy   

Code Science Field
B740  Biomedical sciences  Pharmacological sciences, pharmacognosy, pharmacy, toxicology 
Keywords
LPS; peptidic inhibitors of LPS; molecular recognition; rational drug design
Evaluation (rules)
source: COBISS
Researchers (4)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  09924  PhD Anton Lavrič  Pharmacy  Researcher  2002 - 2004  57 
2.  17917  PhD Andreja Majerle  Biotechnology  Researcher  2002 - 2004  92 
3.  12060  PhD Primož Pristovšek  Chemistry  Head  2002 - 2004  135 
4.  00830  PhD Anton Štalc  Biotechnology  Researcher  2002 - 2004  158 
Organisations (2)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0104  National Institute of Chemistry  Ljubljana  5051592000  20,869 
2.  0258  Lek Pharmaceutical Company d.d.  Ljubljana  1732811  8,400 
Abstract
Lipopolysaccharide (LPS) triggers a sequence of defense reactions leading to the septic shock that causes more than 100.000 deaths annually in the U.S.A. alone. We will study the binding of known peptidic LPS inhibitors (natural defense peptides or fragments of LPS binding proteins) to LPS using nuclear magnetic resonance (NMR) techniques, and perform computer modeling of the complexes. They will be compared to the structures of the peptide fragments in the parent proteins in cases where their X-ray structure is known, and hypotheses of the pattern of LPS binding to proteins and peptides will be developed. The hypotheses will be tested by synthesis and in vitro activity (i.e. LPS inhibition) measurements of modified peptide sequences. The peptides that perform well in the tests will enter a new cycle of NMR measurements and molecular modeling; additionally, their toxicity will be monitored. The purpose of the project is to set up the basis for the rational design of new peptidic LPS inhibitors.
Views history
Favourite